Sitemap Klarity story Join us Medication Service About us

HSA & FSA accepted; best-value for top quality care

Same-day mental health, weight loss, and primary care appointments available

Excellent

based on 0 reviews

Accept major insurances and cash-pay

HSA & FSA accepted; best-value for top quality care

Same-day mental health, weight loss, and primary care appointments available

Excellent

based on 0 reviews

Accept major insurances and cash-pay

Back

Published: Apr 12, 2026

Does Medicaid cover Mounjaro?

Written by Klarity Editorial Team

Published: Apr 12, 2026

Table of contents

If you’re considering a GLP-1 medication like Wegovy, Ozempic, or Mounjaro for weight loss or diabetes management, one of your first questions is likely: Will my insurance actually cover this? The answer isn’t always straightforward—and understanding the landscape of insurance coverage for these powerful medications can save you thousands of dollars and weeks of frustration.

In this comprehensive guide, we’ll break down exactly how insurance coverage works for GLP-1 drugs, what you can expect from commercial insurance versus Medicare and Medicaid, why prior authorization can be a hurdle, and what to do if you’re denied. We’ll also explore the most affordable self-pay options available in 2025 if insurance won’t step up.

Understanding GLP-1 Medications: What They Are and Who Uses Them

GLP-1 receptor agonists are a class of injectable medications that mimic a natural hormone (glucagon-like peptide-1) to regulate blood sugar and reduce appetite. Originally developed for type 2 diabetes, these drugs gained widespread attention when clinical trials showed they could also produce significant, sustained weight loss.

The three most commonly prescribed GLP-1 medications in the U.S. are:

Wegovy (semaglutide) – FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions
Ozempic (semaglutide) – FDA-approved for type 2 diabetes; widely used off-label for weight loss
Mounjaro (tirzepatide) – FDA-approved for type 2 diabetes; works on both GLP-1 and GIP receptors (its weight-loss formulation is called Zepbound)

These medications have transformed treatment for millions of Americans struggling with obesity and metabolic disease. But there’s a catch: they’re expensive, and insurance coverage is complicated.

The Insurance Coverage Landscape: What You Need to Know

Commercial Insurance: Limited and Highly Restricted

Most private health insurance plans cover GLP-1 medications for diabetes (Ozempic and Mounjaro) but are far more restrictive when it comes to obesity treatment (Wegovy). Here’s why:

Under the Affordable Care Act, diabetes treatment is considered an essential health benefit. That means insurers must cover medications prescribed for type 2 diabetes. However, anti-obesity medications are not mandated benefits—employers and insurers can choose whether or not to include them in their formularies.

The result? According to a 2024 Kaiser Family Foundation analysis, many large employer plans either exclude weight-loss drugs entirely or impose strict limitations due to their high cost—often exceeding $1,000 per month per patient.

What commercial plans typically require for Wegovy coverage:

BMI ≥30 (or ≥27 with at least one weight-related comorbidity like hypertension, type 2 diabetes, or sleep apnea)
Documented evidence of at least 6 months of supervised diet and lifestyle modification attempts
Prior authorization confirming medical necessity
Step therapy in some cases—trying older, cheaper weight-loss medications first
Ongoing monitoring with required weight-loss targets (e.g., ≥5% weight reduction within 3–6 months to continue coverage)

Even when covered, Wegovy is typically placed in Tier 3 or 4 (non-preferred brand or specialty tier), meaning higher out-of-pocket costs—often $100–$400+ per month depending on your plan’s cost-sharing structure.

Medicare: Still Largely Excluded

Under current federal law (the Social Security Act), Medicare Part D cannot cover medications prescribed solely for weight loss. This exclusion has been in place since the program’s inception and applies to all anti-obesity drugs, including Wegovy.

However, there’s an important exception: Medicare will cover these drugs when prescribed for other FDA-approved indications. In March 2024, Medicare announced it would cover Wegovy for patients with established cardiovascular disease and obesity, since the drug received FDA approval to reduce cardiovascular risk in this population. But if you’re simply seeking weight loss without that specific cardiovascular indication, Medicare won’t pay.

For diabetes medications like Ozempic and Mounjaro, Medicare Part D provides coverage when prescribed on-label for type 2 diabetes. These are typically placed on higher formulary tiers with prior authorization requirements to confirm diagnosis and appropriate use.

Medicaid: A Patchwork of State Policies

Medicaid coverage for GLP-1 weight-loss drugs varies dramatically by state. Federal law allows states to exclude ‘drugs used for weight loss’ from their Medicaid formularies, and most do.

As of late 2024, only about 13 states offered any Medicaid coverage for anti-obesity medications—and that number is shrinking. Budget pressures have led several states to roll back coverage:

California: Covered Wegovy with strict prior authorization in 2025, but announced it will discontinue all coverage for weight-loss GLP-1s on January 1, 2026
Pennsylvania: Added coverage in 2023 but is eliminating it in January 2026 due to cost concerns
Texas, Florida, and Illinois: Have never covered weight-loss medications for adults under Medicaid

States that do cover these drugs impose rigorous criteria similar to commercial plans—high BMI thresholds, documented lifestyle interventions, comorbidity requirements, and quantity limits.

One notable exception: Children and adolescents under 21 may still access these medications through Medicaid’s Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit, even in states that don’t cover adults.

The Prior Authorization Process: What to Expect

Prior authorization (PA) is the biggest hurdle most patients face when seeking GLP-1 coverage. Here’s what the process typically looks like:

1. Your Doctor Submits a PA Request

Your healthcare provider sends documentation to your insurance company including:

Your current BMI and medical history
Records of previous weight-loss attempts
Documentation of weight-related comorbidities
Clinical justification for the medication

2. Insurance Reviews the Request

The insurer evaluates whether you meet their specific criteria. This usually takes 5–7 business days for an initial decision, though it can take longer if additional information is needed.

3. Decision and Potential Appeal

You’ll receive approval, denial, or a request for more information. If denied, you have the right to appeal—and appeals can be successful when proper documentation is provided.

Common reasons for denial:

BMI doesn’t meet the threshold
Insufficient documentation of prior weight-loss efforts
Missing comorbidity documentation
Off-label use (e.g., requesting Ozempic for weight loss when you don’t have diabetes)
Plan exclusion of all obesity medications

Tips for a Successful Prior Authorization

Document everything: Keep detailed records of your weight-loss journey, including supervised programs, dietitian visits, and exercise attempts
Emphasize health risks: If you have conditions like prediabetes, hypertension, or sleep apnea, make sure these are clearly documented
Be persistent: If initially denied, work with your doctor to submit additional evidence
Know your plan: Review your insurance formulary and coverage policies before starting the process

At Klarity Health, our providers are experienced in navigating prior authorization requirements and can help document your medical necessity for GLP-1 medications. With transparent pricing and the ability to accept both insurance and cash payments, we make it easier to get the care you need on your terms.

State-by-State Medicaid Coverage Comparison

For those relying on Medicaid, here’s what coverage looks like in key states:

State	Wegovy Coverage Status	Key Restrictions
California	❌ Ending Jan 1, 2026	Previously required BMI ≥30 or ≥27 + comorbidity, 6-month diet program; coverage eliminated due to budget cuts
Texas	❌ Not Covered	All obesity medications excluded for adults ≥21; EPSDT exception for children
Florida	❌ Not Covered	State exercises federal exclusion; no anti-obesity drugs covered
New York	✅ Covered with PA	Requires BMI ≥30 or ≥27 + comorbidity, documented lifestyle modification, quantity limits apply
Pennsylvania	⚠️ Ending Jan 2026	Currently covered with strict PA; scheduled for elimination due to cost
Illinois	❌ Not Covered	No Medicaid coverage (state employee coverage expanded, but not Medicaid)

The trend is clear: states are pulling back on obesity drug coverage as costs escalate. If you’re on Medicaid and considering GLP-1 therapy, act quickly and check your state’s current policy, as it may change with the new year.

What to Do If Insurance Denies Your Claim

A denial doesn’t have to be the end of the road. Here are your options:

Appeal the Decision

Most denials can be appealed, and success rates improve when you provide comprehensive documentation. Your appeal should include:

A detailed letter from your physician explaining medical necessity
Updated BMI measurements and comorbidity documentation
Records of previous weight-loss attempts and their outcomes
Any relevant lab work (A1c, cholesterol, blood pressure readings)
Published studies supporting GLP-1 use for your specific situation

Consider Alternative Medications

If your insurance won’t cover Wegovy but covers diabetes medications, and you have prediabetes or metabolic syndrome, your doctor might be able to prescribe Ozempic or Mounjaro on-label for those conditions (though this approach has limitations and ethical considerations).

Explore Manufacturer Savings Programs

Both Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Mounjaro/Zepbound) offer significant assistance:

Novo Nordisk Programs:

Savings card for commercially insured patients: Can reduce copays to as low as $0 for Wegovy (up to $225 off per month)
NovoCare Access Program: For uninsured patients meeting income criteria—may provide free medication
Self-pay pricing: Through participating pharmacies, Wegovy now available for $349/month (down from list price of ~$1,350)

Eli Lilly Programs:

Mounjaro Savings Card: $25/month for up to 12 fills for commercially insured patients with type 2 diabetes
LillyDirect: Cash-pay program offering Zepbound vials at $299–$449/month depending on dose

Leverage GoodRx and Discount Programs

In November 2025, GoodRx announced a groundbreaking partnership with Novo Nordisk offering:

$199/month for the first two months of Wegovy or Ozempic
$349/month ongoing pricing for most doses
Available at nearly all major pharmacies nationwide

This represents a 60–70% discount from list prices and is available to cash-paying patients regardless of insurance status.

Switch to Cash Pay

Sometimes paying out-of-pocket is actually more affordable than dealing with insurance copays and restrictions. With the recent price reductions from manufacturers and discount programs, monthly costs for GLP-1s have dropped significantly for self-pay patients.

Klarity Health offers both insurance billing and transparent cash-pay options, giving you flexibility. Our providers can help you understand which payment method makes the most sense for your situation, and our streamlined telehealth platform means you can access care from anywhere—no need to navigate complex insurance networks just to get a consultation.

Telehealth and Insurance: Getting Virtual Care Covered

One bright spot in the insurance landscape: telehealth coverage has expanded dramatically since 2020. Most major insurers now cover virtual visits for weight management at the same rate as in-person care.

Key points about telehealth and insurance:

Over 40 states have telehealth parity laws requiring insurers to cover virtual care equivalently to in-person visits
Medicare extended telehealth coverage and now routinely covers virtual consultations for chronic disease management
Nutritional counseling for obesity is an ACA-mandated preventive service—covered at no cost when done in-network, whether virtual or in-person

Important considerations:

Verify your telehealth provider is in-network (or understand out-of-network costs)
Some plans require live video visits (versus phone-only) for coverage
The consultation may be covered even if the medication prescription isn’t

Platforms like Klarity Health make it simple to connect with licensed providers who can evaluate your candidacy for GLP-1 medications, submit prior authorizations to your insurance, and provide ongoing monitoring—all through convenient video visits. This removes geographic barriers and long wait times while still providing high-quality care that insurance recognizes.

Current Self-Pay Pricing: Your Options in 2025

If you decide to pay out-of-pocket or your insurance won’t cover these medications, here’s what you can expect:

Wegovy

List price: ~$1,350/month
GoodRx introductory pricing: $199/month (first 2 months), then $349/month
Novo Nordisk cash program: $349/month through NovoCare
With manufacturer savings card (if commercially insured): Potentially $0 copay with up to $225/month discount

Ozempic

List price: ~$998/month
GoodRx pricing: $199/month (first 2 fills), then $349/month for lower doses; $499/month for 2mg dose
Standard discount coupons: ~$800–$900 at major pharmacies
With Novo savings card (for diabetes): As low as $25/month if commercially insured

Mounjaro

List price: ~$1,080/month
Standard cash price: ~$1,000–$1,200
With Lilly savings card (for diabetes): $25/month for commercially insured patients
Zepbound vials (weight-loss formulation): $299–$449/month via LillyDirect

These pricing changes represent a significant shift in accessibility. Where GLP-1s were once financially out of reach for most self-pay patients, manufacturer competition and public pressure have brought prices down to levels many can afford—often cheaper than high-deductible insurance copays.

FAQ: Your GLP-1 Insurance Questions Answered

Q: Will my insurance cover Wegovy if I have a BMI of 28 and high blood pressure?

A: Possibly. Most plans require either BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity (like hypertension). You’ll still need prior authorization and documentation of previous weight-loss attempts, but you likely meet the medical criteria.

Q: Can I use my FSA or HSA to pay for these medications?

A: Yes! Whether insurance-covered or self-pay, GLP-1 medications prescribed for weight loss or diabetes qualify as eligible medical expenses for Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA).

Q: If my insurance denies Wegovy, can I just get Ozempic instead?

A: Only if you have an FDA-approved indication like type 2 diabetes. Most insurers specifically prohibit off-label use of diabetes medications for weight loss and require diagnosis confirmation. Attempting to bypass this can result in claim denials or even fraud allegations.

Q: How long does insurance approval typically take?

A: Initial prior authorization decisions usually take 5–7 business days. If you appeal a denial, expect 2–3 weeks for a response. Expedited reviews are available in urgent medical situations.

Q: Does insurance cover the telehealth visit to get prescribed these medications?

A: Generally, yes—if your provider is in-network and your plan covers telehealth. Most insurers now treat virtual visits the same as in-person for coverage purposes. The visit copay is typically covered even if the medication itself requires additional authorization.

Q: What happens if I lose weight and want to stop—will insurance cover me again later?

A: This varies by plan. Some insurers limit lifetime coverage or require a waiting period between treatment courses. Others will re-authorize if you regain weight and meet criteria again. Check your specific plan’s policies.

Making Your Decision: Insurance vs. Self-Pay

Choosing between fighting for insurance coverage and paying out-of-pocket is deeply personal and depends on your financial situation. Here’s a framework to help:

Consider pursuing insurance coverage if:

You have commercial insurance with pharmacy benefits
You clearly meet medical criteria (high BMI, documented comorbidities)
You have time to navigate prior authorization (1–3 weeks typically)
Your plan’s copay structure makes it worthwhile (some specialty copays are still $200–$400/month)
You’re prescribed the medication for diabetes, which typically has better coverage

Consider cash-pay options if:

Your insurance explicitly excludes weight-loss medications
You’re on Medicare (which doesn’t cover obesity drugs for most patients)
You’re in a state where Medicaid doesn’t cover these medications
The new discount pricing ($199–$349/month) is competitive with your insurance copay
You want to avoid the hassle and delays of prior authorization
You prefer privacy (insurance claims create records)

Why Klarity Health Can Help:

At Klarity Health, we understand that navigating insurance for GLP-1 medications can be overwhelming. That’s why we offer:

Flexible payment options: We accept both insurance and cash pay, so you can choose the path that works for your budget
Experienced providers: Our clinicians are skilled at documenting medical necessity and submitting prior authorizations
Transparent pricing: You’ll always know what to expect—no surprise bills
Convenient access: Virtual visits mean you can connect with a provider from home, often with same-day or next-day availability

Whether you’re working through insurance or paying out-of-pocket, we’re here to support your weight-loss journey with personalized, accessible care.

The Bottom Line: Know Your Options and Advocate for Yourself

GLP-1 medications like Wegovy, Ozempic, and Mounjaro have proven remarkably effective for weight loss and metabolic health—but insurance coverage remains frustratingly inconsistent. Understanding your plan’s specific policies, meeting documentation requirements, and knowing your self-pay alternatives are essential to accessing these treatments.

Key takeaways:

Commercial insurance usually covers diabetes GLP-1s but restricts obesity medications; expect prior authorization and strict criteria
Medicare generally doesn’t cover weight-loss drugs except for specific cardiovascular indications
Medicaid coverage is limited and shrinking, with only a minority of states offering any obesity medication coverage
Self-pay options have improved dramatically in 2025, with new manufacturer programs and GoodRx discounts bringing monthly costs down to $199–$349 for many patients
Telehealth visits are typically covered by insurance and provide convenient access to prescribers and ongoing care

Don’t let insurance barriers keep you from exploring treatment options. Whether through insurance, manufacturer programs, or affordable cash-pay options, effective weight-loss medications are more accessible than ever before. Start by talking to a knowledgeable healthcare provider who can assess your individual situation and help navigate the path that’s right for you.

Ready to take the first step? Klarity Health connects you with experienced providers who understand both the clinical and insurance sides of GLP-1 therapy. Book a virtual consultation today to discuss your options and get personalized guidance—on your schedule, at a price that works for you.

Research Currency Statement

Verified coverage status and pricing are accurate as of December 17, 2025. Always check your own insurance formulary for the latest details, as policies can change with new plan years.

Top 5 Citations

California DHCS Medi-Cal Announcement – Official notice that Medi-Cal will discontinue covering GLP-1 medications for weight loss (Wegovy, Saxenda, Zepbound) as of January 1, 2026 (www.cmadocs.org)
KFF Issue Brief (Nov 2024) – Comprehensive analysis finding that only 13 states cover anti-obesity medications under Medicaid, with federal law allowing exclusion of weight-loss drugs (www.kff.org)
GoodRx Press Release (Nov 17, 2025) – Announcement of industry-leading $199/month introductory pricing for Wegovy and Ozempic through partnership with Novo Nordisk (www.businesswire.com)
Pennsylvania Health Law Project (2024) – Details PA Medicaid coverage criteria for Wegovy, including BMI ≥30 or ≥27 with comorbidity and 6-month lifestyle modification requirement (www.phlp.org)
Fierce Pharma (Nov & Dec 2025) – Industry reporting on manufacturer price cuts: Novo Nordisk reducing Wegovy/Ozempic self-pay prices to $349/month and Eli Lilly offering Zepbound vials at $299–$449/month (www.fiercepharma.com)

Source:

Looking for support with Weight loss? Get expert care from top-rated providers

Find the right provider for your needs — select your state to find expert care near you.

All professional services are provided by independent private practices via the Klarity technology platform. Klarity Health, Inc. does not provide medical services.

Phone:

(866) 391-3314

— Monday to Friday, 7:00 AM to 4:00 PM PST

Fax:

(855) 975-3008

Email:

patientsupport@helloklarity.com

Mailing Address:

1825 South Grant St, Suite 200, San Mateo, CA 94402

Join our mailing list for exclusive healthcare updates and tips.

Stay connected to receive the latest about special offers and health tips. By subscribing, you agree to our Terms & Conditions and Privacy Policy.